Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 7/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558878 | 0.79 | POLB (0.36) | USP2GAAMAOBCA2PTGS2 | |
| SCHEMBL6782580 | 0.78 | AHR (0.45) | CA2KMT2AALDH1A1CYP3A4 | |
| SCHEMBL5014871 | 0.78 | CHRNB4 (0.38) | USP2GAAKMT2AALDH1A1CYP3A4 | |
| SCHEMBL10788340 | 0.76 | PTGS2 (0.42) | USP2GAAMAOBCA2PTGS2 | |
| SCHEMBL90908 | 0.76 | CREBBP (0.40) | GAAMAOBCA2PTGS2BRD4 | |
| SCHEMBL8282240 | 0.76 | CREBBP (0.40) | GAAMAOBCA2PTGS2BRD4 | |
| SCHEMBL6619829 | 0.75 | CA2 (0.36) | MAOBCA2CA12CA9ALDH1A1 | |
| SCHEMBL8256546 | 0.75 | USP2 (0.40) | USP2GAAMAOBCA2PTGS2 | |
| SCHEMBL7709944 | 0.75 | CYP3A4 (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL13591522 | 0.74 | PTGS2 (0.39) | USP2GAAMAOBCA2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | USP2 3250/4885GAA 2891/4885ACHE 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.